Difference between revisions of "Team:TokyoTech"
| Line 23: | Line 23: | ||
</div> | </div> | ||
| − | <div style="padding-top: 15px; padding-left: | + | <div style="padding-top: 15px; padding-left: 25px;"> |
| − | <div id="contents"> | + | <div id="contents" style="z-index: 10"> |
| − | <ul class=" | + | <ul class="click_menu_checkbox vertm_down"> |
| − | + | <li style="margin-bottom: 10px; border: 5px double #fff; border-radius: 10px;"> | |
| − | <input type=" | + | <input type="checkbox" id="vmcb-a" /> |
| − | <label for=" | + | <label for="vmcb-a"><a href="https://2017.igem.org/Team:TokyoTech">Home</a></label> |
</li> | </li> | ||
| − | <li> | + | <li style="margin-bottom: 10px; border: 5px double #fff; border-radius: 10px"> |
| − | <input type=" | + | <input type="checkbox" id="vmcb-b" /> |
| − | <label for=" | + | <label for="vmcb-b"><a href="https://2017.igem.org/Team:TokyoTech/Medal">Achievements</a></label> |
| + | </li> | ||
| + | <li style="margin-bottom: 10px; border: 5px double #fff; border-radius: 10px"> | ||
| + | <input type="checkbox" id="vmcb-c" /> | ||
| + | <label for="vmcb-c"><a>Project</a></label> | ||
<ul> | <ul> | ||
| − | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Description" class="w3-bar-item w3-button w3-hover-white">Description</a></li> | |
| − | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Project/Basic_Parts" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Basic Parts</a></li> | |
| − | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Project/Composite_Parts" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Composite Parts</a></li> | |
| − | + | ||
</ul> | </ul> | ||
</li> | </li> | ||
| − | <li> | + | <li style="margin-bottom: 10px; border: 5px double #fff; border-radius: 10px"> |
| − | <input type=" | + | <input type="checkbox" id="vmcb-d" /> |
| − | <label for=" | + | <label for="vmcb-d"><a>Experiment</a></label> |
<ul> | <ul> | ||
| − | + | <li> | |
| − | + | <input type="checkbox" id="vmcb-d1" /> | |
| − | + | <label for="vmcb-d1"><a style="text-align: center;">Bacteria to <br> Human Cells</a></label> | |
| − | <li><a href="https://2017.igem.org/Team:TokyoTech/Experiment/AHK4_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">AHK4 Assay</a></li> | + | <ul> |
| + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraI Assay</a></li> | ||
| + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraI_Improvement" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">TraI <br> Impovement</a></li> | ||
| + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/TraR_Reporter_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white" >TraR Reporter <br> Assay</a></li> | ||
| + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/Transcriptome_Analysis" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Transcriptome <br> Analysis</a></li> | ||
| + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/C8_Toxicity" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">C8 Toxicity <br> Assay</a></li> | ||
| + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Experiment/Chimeric_Transcription_Factor" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Chimeric <br> Transcription <br> Factor</a></li> | ||
| + | </ul> | ||
| + | </li> | ||
| + | <li><input type="checkbox" id="vmcb-d2" /> | ||
| + | <label for="vmcb-d2"><a style="text-align: center;">Human Cells to Bacteria</a></label> | ||
| + | <ul> | ||
| + | <li><a href="https://2017.igem.org/Team:TokyoTech/Experiment/AHK4_Assay" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">AHK4 Assay</a></li> | ||
| + | </ul> | ||
| + | </li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
| − | <li> | + | <li style="margin-bottom: 10px; text-align: center; border: 5px double #fff; border-radius: 10px"> |
| − | <input type=" | + | <input type="checkbox" id="vmcb-e" /> |
| − | <label for=" | + | <label for="vmcb-e"><a href="https://2017.igem.org/Team:TokyoTech/Model">Modelling</a></label> |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</li> | </li> | ||
| − | <li> | + | <li style="margin-bottom: 10px; text-align: center; border: 5px double #fff; border-radius: 10px"> |
| − | <input type=" | + | <input type="checkbox" id="vmcb-f" /> |
| − | <label for=" | + | <label for="vmcb-f"><a>Human Practices</a></label> |
<ul> | <ul> | ||
| − | <li><a href="https://2017.igem.org/Team:TokyoTech/HP" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Overview</a></li> | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Overview</a></li> |
| − | <li><a href="https://2017.igem.org/Team:TokyoTech/HP/Silver" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Silver</a></li> | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP/Silver" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Silver</a></li> |
| − | <li><a href="https://2017.igem.org/Team:TokyoTech/HP/ | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/HP/Gold_Integrated" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Integrated <br> Human Practice</a></li> |
| − | <li><a href="https://2017.igem.org/Team:TokyoTech/Collaborations" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Collaborations</a></li> | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Collaborations" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Collaborations</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
| − | <li> | + | <li style="margin-bottom: 10px; text-align: center; border: 5px double #fff; border-radius: 10px"> |
| − | <input type=" | + | <input type="checkbox" id="vmcb-g" /> |
| − | <label for=" | + | <label for="vmcb-g"><a>About us</a></label> |
<ul> | <ul> | ||
| − | <li><a href="https://2017.igem.org/Team:TokyoTech/Team" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Team</a></li> | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Team" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Team</a></li> |
| − | <li><a href="https://2017.igem.org/Team:TokyoTech/Attributions" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Attributions</a></li> | + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Attributions" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Attributions</a></li> |
| + | <li style="text-align: center;"><a href="https://2017.igem.org/Team:TokyoTech/Sponsors" onclick="w3_close()" class="w3-bar-item w3-button w3-hover-white">Sponsors</a></li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
Revision as of 11:47, 30 October 2017
<!DOCTYPE html>
Overview
Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
Project
Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
Modeling
Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
Human Practices
Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
Notebook
Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
Team
Gene therapy has been expected in cancer therapy for years. An interesting therapy for cancer using anaerobic bacteria as a carrier has been developed, but after the anaerobic cancer region is diminished, the bacteria cannot stay there anymore. If anti-cancer bacteria can stay in affected area, they promptly respond to cancer recurrence. Co-existence of bacteria and host cells should be quite difficult in our body or human cell culture systems, because bacteria grow so fast. It is important to control bacterial proliferation in them. So, we try to establish a new living system that human cells control the population of bacteria by engineering the both cells by creating two signaling pathways of 1) Bacteria-Mammals and 2) Bacteria-Plants. We expect that this system will lead to a new experimental approach and a new medical therapy. Moreover, we imagine about "A boundary between cellular groups and living organisms" with general public.
Sponsers
JASSO
Kuramae Kougyoukai
IDT
Hajime Fujita: All Rights Reserved
